VEGFR2, PDGFRα, and FGFR1 Receptor Tyrosine Kinase Group (VEGFR2, PDGFRα, FGFR1 Group)

VEGFR2, PDGFRα, and FGFR1 are three distinct cell-surface receptor tyrosine kinases that mediate the effects of vascular endothelial growth factors, platelet-derived growth factors, and fibroblast growth factors, respectively. While frequently studied and targeted together (e.g., by multi-kinase inhibitors) due to their pivotal roles in angiogenesis, cell proliferation, and cancer biology, it is important to note that this entry represents them as a *grouping* of individual targets, not as a single unified molecule. Each receptor is chemically and functionally distinct, and there is no canonical alias for this combined entity. They share similar molecular mechanisms involving ligand-induced dimerization, autophosphorylation, and activation of downstream signaling pathways such as PI3K/Akt, MAPK, and PLCγ1. Therapeutic agents targeting these receptors have demonstrated efficacy in cancer, fibrotic disorders, and vascular diseases, though side effects related to vascular and organ toxicity are common. Cross-talk and regulatory interactions among these receptors exist, particularly in endothelial signaling.

Inhibition of receptor phosphorylation; Blockade of ligand binding; Downregulation of angiogenic and mitogenic signaling pathways; VEGF ligand trapping by antibodies or fusion proteins